마이크로웨이브법에 의해 제조된 HAp 및 BCP 분말이 뼈모세포 및 파골세포의 활성에 미치는 영향

송호연; 민영기; 양훈모; 맹주양; Ho-Yeon Song; Young-Ki Min; Hun-Mo Yang; Joo-Yang Mang

Korean Journal of Materials Research, Vol.17, No.12, 669-675, December, 2007

DOI10.3740/MRSK.2007.17.12.669 Export Citation

마이크로웨이브법에 의해 제조된 HAp 및 BCP 분말이 뼈모세포 및 파골세포의 활성에 미치는 영향

The Effects of HAp and BCP Nano Powders Synthesized by Microwave-Assisted Synthesis on the Activation of Osteoblast and Osteoclast

송호연^†, 민영기¹, 양훈모¹, 맹주양²

순천향대학교 의과대학 미생물학교실
¹순천향대학교 생리학교실
²순천향대학교 화학과

Ho-Yeon Song^†, Young-Ki Min¹, Hun-Mo Yang¹, and Joo-Yang Mang²

Department of Microbiology, Soonchunhyang University, 366-1 Ssangyoung-dong, Cheonan City, Chungnam, 330-090, Korea
¹Department of Physiology, School of Medicine, Soonchunhyang University, 366-1 Ssangyoung-dong, Cheonan City, Chungnam, 330-090, Korea
²Department of Chemistry, Soonchunhyang University, 366-1 Ssangyoung-dong, Cheonan City, Chungnam, 330-090, Korea

E-mail:

Hydroxyapatite (HAp) and biphasic calcium phosphate (BCP) nano powders were synthesized using the microwave-assisted synthesis process dependent on pH and microwave irradiation time. The average size of a powder was less than 100 nm in diameter. Through in-vitro cytotoxicity tests by an extract dilution method, the HAp and BCP nano powders have shown to be cytocompatible for L-929 fibroblast cells, osteoblastlike MG-63 cells and osteoclast-like Raw 264.7 cells. The activation of osteoblast was estimated by alkaline phosphatase (ALP) activity. When the HAp and BCP were treated to MG-63 cells, alkaline phosphatase activities increased on day 3, compared with those of the untreated cells. Also, the collagen fibers increased when the HAp and BCP powders suspension were treated to MG-63 cells, compared to those of the untreated cells. Quantitative alizarin red S mineralization assays showed a trend toward increasing mineralization in osteoblast cultured with powder suspension. In conclusion, hydroxyapatite and biphasic calcium phosphate appeared to be a bone graft substitute material with optimal biocompatibility and could be further applied to clinical use as an artificial bone graft substitute.

Keywords:Hydroxyapatite;Biphasic calcium phosphate;Microwave;Biocompatibility

[References]

Suh H, Tissue engineering for artificial organs, 40, 13, Yonsei Univ., Korea (1999). (1999)
lesson TS, Lesson CR, Histollgy, 4th ed., p.115-145, Saunders WB Company, Canada, (1981). (1981)
Burchardt H, Clin Orthop Relat Res., 174, 28 (1983)
Hughes SP, Benson MK, Colton CL, Orthopaedics: The principles and Parctice of Musculoskeletal surgery, p500-535, Churchill Livingstone, New York, (1987). (1987)
McGee TD, Kor. J. of Ceram., 7(1), 41 (2001)
Hiatt WH, Schallhorn RG, J. Periodontol., 42, 642 (1971)
Groot K, Bioceramics of calcium phosphate, Boca Raton, FL: CRC press Inc, 1983. (1983)
Ducheyne P, Qiu Q, Biomaterials, 20, 2287 (1999)
Lee JE, Park JC, Kim YH, Suh H, Biomet Res., 2(2), 65 (1998)
Yang YI, Kim YK, Park KD, Lee JW, Jo IH, Kim YJ, Biomaterials, 25, 527 (2004)
Bouler JM, Guicheux J, Pilet P, Weiss P, Dawlsi G, J. Mater. Sci. Mater. Med., 12(5), 385 (2001)
Bruijn JD, Groot K, Zhang X, Biomaterials, 22(19), 2617 (2001)
Chris Arrts JJ, Verdonschot N, Schreurs BW, Biomaterials, 27, 1110 (2006)
ISO 10993, Biological evaluation of medical devices-Part 5: Test for cytotoxicity: in vitro methods.
Christ Arrts JJ, Verdonschot N, Schreurs BW, Buma P, Biomaterials, 27(15), 2951 (2006)
Stanford CM, Jacobson PA, Eanes ED, Lembke LS, Misure RJ, J Biological Chemistry, 270(16), 9420 (1995)
Ratisoontorn C, Seto ML, Broughton KM, Cunningham ML, Bone, 36(4), 627 (2005)
Higashi S, Yamamuro T, Nakamura T, Ikada Y, Hyon SH, Jamshidi K, Biomaterials, 7(3), 183 (1986)
Albee FH, Ann Sur, 71, 33 (1920)
Declercq H, Verken NV, Maeyer ED, Biomaterials, 25, 757 (2004)
Boskey AL, Conn Tissue Res., 36, 357 (1996)

[Referenced By]

[1] Suh H, Tissue engineering for artificial organs, 40, 13, Yonsei Univ., Korea (1999). (1999)

[2] lesson TS, Lesson CR, Histollgy, 4th ed., p.115-145, Saunders WB Company, Canada, (1981). (1981)

[3] Burchardt H, Clin Orthop Relat Res., 174, 28 (1983)

[4] Hughes SP, Benson MK, Colton CL, Orthopaedics: The principles and Parctice of Musculoskeletal surgery, p500-535, Churchill Livingstone, New York, (1987). (1987)

[5] McGee TD, Kor. J. of Ceram., 7(1), 41 (2001)

[6] Hiatt WH, Schallhorn RG, J. Periodontol., 42, 642 (1971)

[7] Groot K, Bioceramics of calcium phosphate, Boca Raton, FL: CRC press Inc, 1983. (1983)

[8] Ducheyne P, Qiu Q, Biomaterials, 20, 2287 (1999)

[9] Lee JE, Park JC, Kim YH, Suh H, Biomet Res., 2(2), 65 (1998)

[10] Yang YI, Kim YK, Park KD, Lee JW, Jo IH, Kim YJ, Biomaterials, 25, 527 (2004)

[11] Bouler JM, Guicheux J, Pilet P, Weiss P, Dawlsi G, J. Mater. Sci. Mater. Med., 12(5), 385 (2001)

[12] Bruijn JD, Groot K, Zhang X, Biomaterials, 22(19), 2617 (2001)

[13] Chris Arrts JJ, Verdonschot N, Schreurs BW, Biomaterials, 27, 1110 (2006)

[14] ISO 10993, Biological evaluation of medical devices-Part 5: Test for cytotoxicity: in vitro methods.

[15] Christ Arrts JJ, Verdonschot N, Schreurs BW, Buma P, Biomaterials, 27(15), 2951 (2006)

[16] Stanford CM, Jacobson PA, Eanes ED, Lembke LS, Misure RJ, J Biological Chemistry, 270(16), 9420 (1995)

[17] Ratisoontorn C, Seto ML, Broughton KM, Cunningham ML, Bone, 36(4), 627 (2005)

[18] Higashi S, Yamamuro T, Nakamura T, Ikada Y, Hyon SH, Jamshidi K, Biomaterials, 7(3), 183 (1986)

[19] Albee FH, Ann Sur, 71, 33 (1920)

[20] Declercq H, Verken NV, Maeyer ED, Biomaterials, 25, 757 (2004)

[21] Boskey AL, Conn Tissue Res., 36, 357 (1996)